These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36483043)

  • 21. Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.
    Zhong Y; Wei Q; Lu Y; Tang X; Wang Z; Chen L
    J Thorac Dis; 2020 Oct; 12(10):6016-6022. PubMed ID: 33209434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
    Li Y; Sun Z; Sun W; Wang H; Zu J
    Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhang K; Ma X; Gao H; Wang H; Qin H; Yang S; Liu X
    Cancer Manag Res; 2020; 12():3409-3417. PubMed ID: 32494205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma.
    Song Y; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; He J; Huang J
    Cancer Biol Med; 2021 Mar; 18(2):562-8. PubMed ID: 33724741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
    He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
    Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
    Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
    Front Oncol; 2022; 12():939343. PubMed ID: 35965587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
    Wang L; He Z; Yang S; Tang H; Wu Y; Li S; Han B; Li K; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Sun Y; Wang Q
    Transl Lung Cancer Res; 2019 Oct; 8(5):575-583. PubMed ID: 31737494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib.
    Liu J; Li S; Zhang S; Yang C; Zhang L; Zhang B; Cheng Y; Wang C
    J Thorac Dis; 2020 Oct; 12(10):5765-5773. PubMed ID: 33209408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
    Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
    Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
    [No Abstract]   [Full Text] [Related]  

  • 30. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.
    Wang J; Zhao Y; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Yu H; Zhao Y; Chen W; Luo Y; Wang X; Nan K; Jin F; Dong J; Li B; Liu Z; Han B; Li K
    Cancer Biol Med; 2018 Nov; 15(4):443-451. PubMed ID: 30766754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
    Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
    Front Oncol; 2022; 12():885350. PubMed ID: 35860585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
    Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
    Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib.
    Chen R; Lu FY; Liu B; Huang J; Zhou M; Dai R; Guo Y
    Cancer Manag Res; 2021; 13():3619-3627. PubMed ID: 33976572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
    Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
    Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
    [No Abstract]   [Full Text] [Related]  

  • 37. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
    Jiang HT; Li W; Zhang B; Gong Q; Qie HL
    Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.